View Post

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer. Athenex, Inc. held a Type A meeting with the FDA to discuss …

View Post

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

In Clinical Studies News by Barbara Jacoby

Source: Sorrento Therapeutics, Inc. From: apnews.com Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. This Phase 1 dose-escalation study, approved by the South Korean Ministry …

View Post

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

In In The News by Barbara Jacoby

From: businesswire.com Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update Biotheranostics, Inc. announces recommendations for Breast Cancer Index …

View Post

ONC201 Continues to Show Excellent Safety When Dosed Weekly

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced the successful completion of the dose escalation phase of a clinical trial for the company’s lead molecule ONC201 using weekly dosing.  Oncoceutics has previously reported the exceptional safety profile for ONC201 in multiple clinical trials using a dosing regimen of once every three weeks. The weekly cohort was part of a trial entitled “Oral ONC201 in Treating …

View Post

Guided Therapeutics Expands LuViva® Advanced Cervical Scan Distribution in Latin America

In In The News by Barbara Jacoby

Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company continues to expand in international markets with the signing of a distributor for the Dominican Republic for the LuViva® Advanced Cervical Scan. “We continue to focus on markets that need a better way of screening for cervical …

View Post

Olympic Gold-Medalist and Breast Cancer Survivor Dorothy Hamill Launches BeWisER+ About Breast Cancer

In In The News by Barbara Jacoby

Partnership with bioTheranostics Aims to Encourage Breast Cancer Survivors to Learn How to Work With Their Doctor to Personalize Their Breast Cancer Journey Campaign Supports Survivors with $10,000 Donation to Breastcancer.org SAN DIEGO, CA, January 13, 2016 – Olympic gold-medalist and breast cancer survivor, Dorothy Hamill has partnered with bioTheranostics to launch BeWisER+ About Breast Cancer (www.bewiseraboutbreastcancer.org), an educational campaign …

View Post

GIVE The Gift of a Miracle this Holiday with Chico’s FAS, Inc.

In In The News by Barbara Jacoby

Chico’s FAS, Inc., and our family of brands – Chico’s, White House Black Market, Soma and Boston Proper –  announce their second annual Holiday Miracle Campaign to raise awareness and funds for Children’s Miracle Network Hospitals (CMN Hospitals) across the United States and Canada. In the spirit of the holidays, each boutique will be collecting donations at the register and …

View Post

ASCO: Studies Demonstrate Predictive Power of bioTheranostics’ Breast Cancer Index Molecular Test in Treatment Decisions

In In The News by Barbara Jacoby

Ability to Predict Benefit from Extended Endocrine Therapy Impacts Treatment & Reduces Patient Anxiety bioTheranostics, Inc., today announced results from studies being presented at the 2015 American Society of Clinical Oncology (ASCO) meeting reinforcing the role its Breast Cancer Index (BCI) molecular test plays in informing decisions about extending endocrine therapy beyond five years post-diagnosis for patients with early stage, estrogen receptor-positive …

View Post

ONC201 Trial Featured in 2015 ASCO Conference

In In The News by Barbara Jacoby

Hummelstown, PA (May 26, 2015) – Oncoceutics, Inc. announced that details of a clinical phase I study in advanced solid tumors of its lead compound, ONC201, will be presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 30. The clinical study is being conducted at Rutgers Cancer Institute of New Jersey …

ZIOPHARM Presents Encouraging Data

In In The News by Barbara Jacoby

From: zacks.com ZIOPHARM Oncology, Inc. presented encouraging data on its oncology candidate Ad-RTS-IL-12 at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT). The company stated that Ad-RTS-IL-12 demonstrated potent anti-tumor and anti-cancer stem cell effects in glioma (brain cancer) preclinical and clinical studies. Reduction in tumor mass was observed with Ad-RTS-IL-12 arm as compared to …